Federal Circuit Hearing in Arbutus vs. Moderna Set to Address Key Patent Law and Biotechnology Implications
The upcoming Federal Circuit hearing in the case between Arbutus Biopharma Corp. and Moderna Inc., scheduled for November 5, 2026, is poised to address several pivotal issues that could significantly influence patent law and the biotechnology sector. The dispute centers on allegations that Moderna’s COVID-19 vaccine infringed upon Arbutus’s lipid nanoparticle (LNP) technology patents, with…